Oligometastasis: More Lessons to Be Learned

참고문헌 (25)

1. Hellman S, "Oligometastases", J Clin Oncol, 13, pp.8~10 (1995)
2. 임채홍, "Role of Local Treatment for Oligometastasis: A Comparability Based Meta-Analysis", Cancer Research and Treatment, 54(4), pp.953~969 (2022), 대한암학회[DOI]
3. Katipally RR, "The oligometastatic spectrum in the era of improved detection and modern systemic therapy", Nat Rev Clin Oncol, 19, pp.585~599 (2022)
4. Vivian S. Tan, "Top Ten Lessons Learned from Trials in Oligometastatic Cancers", Cancer Research and Treatment, 55(1), pp.5~14 (2023), 대한암학회[DOI]
5. "Central nervous system cancers (version 2.2022)" (2022)[URL]
6. Ashram S, "Planning trade-offs for SABR in patients with 4 to 10 metastases : a substudy of the SABR-COMET-10 randomized trial", Int J Radiat Oncol Biol Phys, 114, pp.1011~1015 (2022)
7. Palma DA, "Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers : long-term results of the SABR-COMET phase II randomized trial", J Clin Oncol, 38, pp.2830~2838 (2020)
8. Iyengar P, "Consolidative radiotherapy for limited metastatic non-small-cell lung cancer : a phase 2 randomized clinical trial", JAMA Oncol, 4, pp.e173501~ (2018)
9. Gomez DR, "Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer : long-term results of a multi-institutional, phase II, randomized study", J Clin Oncol, 37, pp.1558~1565 (2019)
10. Joseph RW, "Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab", Clin Cancer Res, 24, pp.4960~4967 (2018)
11. Huang AC, "T-cell invigoration to tumour burden ratio associated with anti-PD-1 response", Nature, 545, pp.60~65 (2017)
12. Kim J, "A comparison of 2 disease burden assessment methods(3d volume versus the number of lesions)for prognostication of survival in metastatic melanoma : implications for the characterization of oligometastatic disease", Int J Radiat Oncol Biol Phys, 114, pp.883~891 (2022)
13. Willmann J, "Distant metastasis velocity as a novel prognostic score for overall survival after disease progression following stereotactic body radiation therapy for oligometastatic disease", Int J Radiat Oncol Biol Phys, 114, pp.871~882 (2022)
14. Harrow S, "Stereotactic radiation for the comprehensive treatment of oligometastases(SABR-COMET) : extended long-term outcomes", Int J Radiat Oncol Biol Phys, 114, pp.611~616 (2022)
15. Wang XS, "Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC", J Natl Cancer Inst (2022)[DOI]
16. Kim KH, "A multicenter two-arm, phase II trial assessing the safety and efficacy of first-line lazertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancer(ABLATE, KCSG-LU21-11)", Clin Lung Cancer, 23, pp.e536~9 (2022)
17. Diez P, "UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy", Clin Oncol(R Coll Radiol), 34, pp.288~300 (2022)
18. 이대호, "Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment", Cancer Research and Treatment, 54(4), pp.951~952 (2022), 대한암학회[DOI]
19. McBride S, "Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma", J Clin Oncol, 39, pp.30~37 (2021)
20. Theelen WS, "Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer : results of the PEMBRO-RT phase 2 randomized clinical trial", JAMA Oncol, 5, pp.1276~1282 (2019)
21. Corkum MT, "Can polymetastatic disease be ARRESTed using SABR? A dosimetric feasibility study to inform development of a phase 1 trial", Adv Radiat Oncol, 6, pp.100734~ (2021)
22. Grimm J, "High dose per fraction, hypofractionated treatment effects in the clinic(HyTEC) : an overview", Int J Radiat Oncol Biol Phys, 110, pp.1~10 (2021)
23. Guckenberger M, "Characterisation and classification of oligometastatic disease : a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation", Lancet Oncol, 21, pp.e18~28 (2020)
24. Baker S, "Validation of the prognostic utility of ESTRO", EORTC oligometastatic disease classification : a secondary analysis from the population-based phase II SABR-5 trial, 2022, pp.114, 849~855
25. Willmann J, "Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy : a retrospective single center study", Radiother Oncol, 168, pp.256~264 (2022)

관련 논문AI추천